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Middle East respiratory syndrome coronavirus (MERS-
CoV) is an ongoing emerging infectious disease across the 
Arabian Peninsula, with the majority of cases occurring 
in Saudi Arabia. Through September 23, 2016 the World 
Health Organization reported about 1,806 total cases, 
including 643 deaths from 27 countries (http://www.who. 
int/emergencies/mers-cov/en/). The disease is comprised 
of a lower respiratory infection wherein individuals exhibit 
pneumonia-like symptoms that often lead to multi-organ 
failure and death (1). In addition to close contact with 
infected camels, transmission from human-to-human 
most commonly occurs in the hospital setting through 
close contact between patients and hospital workers (1). 
MERS-CoV has also been isolated from objects within 
patient rooms including bed sheets, bed rails, and IV 
fluid hangers (2), which may all be potential sources of 
transmission. Several cases of MERS-CoV have been 
associated with travelers returning home from the Middle 
East and developing symptoms, including two cases of 
health care workers returning to the United States (3). 
The potential for global spread was recently illustrated by 
a South Korean national returning home from visiting the 
Arabian Peninsula in May, 2015, and initiating an outbreak 
that infected 186 people resulting in 20% mortality and a 
nationwide economic crisis (4). Nonetheless, MERS-CoV 
is not thought to be sustained in the human population 
through human-to-human transmission, but may instead 
be continuously re-introduced into the human population 
from a zoonotic source, most likely dromedary camels 
because of high seropositive rates in herds throughout 
the Middle East (5,6). As camels are integral to the Saudi 
Arabian culture and economy, nationwide culling of camel 
herds is not feasible. Consequently, camel vaccination is 
being considered (7); however, therapeutic strategies have 
primarily focused on interfering with MERS-CoV infection 
in humans (3,5).
To date, therapeutic strategies have been limited to a 
combination of ribavirin and interferon therapies with 
little evidence of efficacy (5). The predominant form of 
support continues to be palliative care including oxygen 
delivery through standard ventilation, or extracorporeal 
membrane oxygenation (ECMO) in more severe cases that 
have progressed to acute respiratory distress syndrome 
(ARDS). A number of human neutralizing antibodies 
directed to MERS-CoV are under development (5), and 
a phase I clinical trial has recently been initiated using a 
transchromosomal bovine production system to produce 
human polyclonal MERS-CoV antibodies (8). Considering 
that diagnosed cases of MERS-CoV typically present to 
hospital 5−10 days after initial infection, MERS-CoV-
directed therapies, such as neutralizing antibodies, may 
be outside the therapeutic window for effectively quelling 
development of an immune pathologic ARDS disease 
phenotype. In hospital diagnosed cases, and early detected 
contact-traced infections, host-directed therapeutic 
interventions may be most beneficial. Nonetheless, 
neutralizing antibody therapy could provide a highly 
effective prophylactic treatment in hospital staff that 
work closely with infected individuals. While therapeutic 
intervention can be an effective strategy for immediate 
response to newly diagnosed cases in the hospital setting, 
widespread prophylactic treatment is not practical. 
The most effective prophylactic treatment would be 
development of an efficacious vaccine.
A MERS-CoV vaccine that can elicit a proper adaptive 
immune response to provide long-term protection may 
be most beneficial to the population across the Arabian 
Peninsula, especially when considering the persistent 
threat of re-introduction of MERS-CoV from dromedary 
camels. More than a decade of work on coronavirus 
vaccines have demonstrated that the spike protein, the 
major determinant of viral tropism, can elicit strong 
neutralizing antibody responses that are effective at 
protecting model organisms against challenge with 
homologous SARS-CoVs (9). Protective T cell responses 
targeting the nucleocapsid protein have also proven effective 
for preventing death, but not clinical disease in SARS-CoV 
infected rodents (10). Building upon knowledge from SARS-
CoV vaccines Muthumani et al. developed a novel DNA 
vaccine designed to elicit adaptive immune responses to 
the MERS-CoV spike protein (11). To enhance the success 
of their DNA vaccine Muthumani et al. built a consensus 
spike protein derived from MERS-CoV spike genomic 
sequences that represent both clades A and B. Vaccine 
efficacy was evaluated in three different mammalian species 
using a 3 dose delivery regimen (a prime and two boosts): 
mice (2 weeks intervals), three dromedary camels (4 weeks 
intervals), and rhesus macaques (3 weeks intervals) (11). 
An important gauge of vaccine efficacy is the cellular and 
humoral, adaptive immune responses that are elicited 
specifically to the MERS-CoV spike protein. Muthumani 
et al. identified a set of immunodominant MERS-CoV-
specific spike epitopes that convincingly activate CD4+ 
and CD8+ T cells isolated from vaccinated mice and non-
human primates (NHPs) (11). Cellular immune responses 
were not evaluated from vaccinated camels. Humoral 
immune responses were evaluated in mice, camels, and 
NHPs. The most effective measure of a humoral immune 
response to a viral antigen is the capacity of the vaccine 
to elicit antibodies that can neutralize viral infectivity 
on cellular assays. All DNA-spike vaccinated mice and 
NHPs generated antibodies capable of neutralizing the 
EMC/2012 strain of MERS-CoV (11). The vaccine appears 
to be less effective in camels, which exhibited varying 
degrees of neutralizing activity, and a lack of neutralizing 
activity in 1 of 3 vaccinated camels. Muthumani et al. 
extended the humoral response observed for MERS-CoV 
to determine if serum could neutralize heterotypic spike 
proteins from human coronaviruses NL63 and HKU1, 
which are commonly associated with mild-upper respiratory 
tract infections (11). Serum from mice and NHPs could 
effectively neutralize both NL63 and HKU1 spike proteins 
in neutralization assays designed around pseudotyped 
lentiviral vector particles (11). However, as recognized by 
Muthumani et al., these assays may not reflect the activity 
that an antibody may exhibit against the spike protein 
presented in its native coronavirus context (11), and others 
have shown that cross neutralization between coronavirus 
genus and species is lacking when live virus is used (12). 
Overall, Muthumani et al. convincingly demonstrate that 
the consensus MERS-CoV DNA spike vaccine can elicit 
effective adaptive immune responses in both mice and 
NHPs, and to a lesser extent in camels. 
The generation of adaptive immune across multiple 
mammalian species provides strong preclinical support 
for translation of the MERS-CoV DNA spike vaccine 
platform to human application. It also offers hope that a 
vaccine will soon be eminent for the prevention of MERS-
CoV infection both in humans and in reservoir animal 
species. However, the true barometer for vaccine efficacy 
is how well a vaccinated animal model is protected from 
development of disease symptoms following challenge 
of an infectious dose of MERS-CoV. This, in turn, can 
be complicated by the availability of animal models that 
accurately reflect MERS-CoV pathology in humans. 
Accordingly, proper model development requires an 
understanding of MERS-CoV pathology in humans. A 
clear picture of MERS-CoV pathogenesis in humans 
has been hampered by cultural constraints that prevent 
autopsy and procurement of human samples from fatal 
cases in Saudi Arabia. In January, 2016 a single publication 
described the histopathologic, immunohistochemical, and 
ultrastructural findings of a single fatal case of MERS-
CoV in the United Arab Emirates (13). MERS-CoV 
antigen was detected in the lungs having histopathology 
consistent with diffuse alveolar damage associated with 
ARDS, and no detection of MERS-CoV antigen in 
extrapulmonary tissues (13). Therefore, an efficacious 
vaccine platform could minimally be anticipated to protect 
a model organism from pathology consistent with MERS-
CoV-induced ARDS. Recently, a new mouse model has 
been described which reproduces severe end stage lung 
disease phenotypes like ARDS, providing a new mouse 
model for prophylatic and therapeutic testing as well (14). 
Muthumani et al. challenged vaccinated rhesus macaques 
with the MERS-CoV EMC/2012 strain (11). Animals 
vaccinated with the control vector exhibited clinical 
signs of disease, radiological evidence of lung disease, 
and histopathology indicative of viral pneumonia. The 
consensus DNA-spike vaccine protected NHPs from 
MERS-CoV-induced disease by reducing viral replication in 
the lungs of infected NHPs. Muthumani et al. demonstrate 
that a consensus MERS-CoV spike DNA vaccine platform 
can effectively elicit cellular and humoral immune responses 
that can protect NHPs from disease (11). The Muthumani 
et al. study provided preclinical efficacy data required by 
the Food and Drug Administration (FDA) to progress the 
vaccine forward into clinical trials. In February of 2016 
the Walter Reed Army Institute of Research (WRAIR) 
announced initiation of the first phase I clinical trial to 
test the safety and immune response of this MERS-CoV 
DNA vaccine platform in people. The phase I clinical trial 
is being executed as collaboration between WRAIR and a 
DNA-based immunotherapy platform developed at Inovio. 
The Inovio platform comprises an algorithm optimized to 
determine an appropriate consensus sequence, as done for 
the MERS-CoV spike protein. 
In 2016 Inovio utilized its proprietary platform to 
initiate phase I clinical DNA vaccine studies for MERS-
CoV, Zika virus, and Ebola virus (http://www.inovio.com/). 
DNA vaccines provide a number of advantages over other 
vaccine approaches such as recombinant protein and live-
attenuated vaccines: (I) development is more cost effective 
and easier; (II) there is no risk of reversion; (III) membrane 
protein targets (e.g., viral membrane glycoproteins) can be 
readily expressed in mammalian cells; and (IV) prior phase 
I clinical studies indicate that there is little inflammation/
toxicity associated with a DNA vaccine (15). Despite these 
advantages, there are no approved DNA vaccines for use 
in humans. DNA vaccines that elicit an effective immune 
response to infectious disease antigens continues to be a 
challenge in humans, as described in a number of former 
clinical trials (15). Tregoning et al. describe impediments in 
the DNA vaccine field that may have contributed to the lack 
of success in previous clinical trials (15), including: (I) the 
inability to adequately scale-up production; (II) differences 
in innate immune responses, between mammalian models 
and humans, which are required to initiate an appropriate 
adaptive immune response; (III) optimized methods of 
delivery (recognized as one of the biggest challenges 
in the field); and (IV) effective protein expression. 
The preclinical study by Muthumani et al. successfully 
addresses impediments 1, 2, and 4 by demonstrating the 
capacity to elicit effective adaptive immune responses in 
a small mammal (mice), a medium sized mammal (rhesus 
macaque), and a large mammal (dromedary camels) (11). To 
address impediment three Inovio developed a proprietary 
electroporation technology to achieve efficient delivery 
of vaccine plasmid DNA to the nucleus of cells, where 
expression of viral immunogen occurs. With numerous 
DNA vaccine trials underway, let us all hope that the 
efficacy of this vaccine platform in humans will be revealed 
within the next 2 years.
 DNA vaccine platforms are an efficient means to rapidly 
respond to emerging infectious diseases (e.g., vaccines in 
clinical trials in 2016 for Zika virus, MERS-CoV, and Ebola 
virus). In the concluding remarks we would like to address 
concerns that may influence long-term efficacy and safety 
profiles of DNA vaccines. Early preclinical studies in animal 
models raised potential safety concerns (16) that were 
later adopted by the FDA as guidance for industry when 
addressing immunogenicity and safety of a DNA delivery 
platform (17). Some of the safety concerns raised include: 
(I) garnering an understanding of the biodistribution,
persistence, and integration profiles potentially associated
with the delivery of any DNA molecule into the nucleus
of a mammalian cell; (II) potential for autoimmunity; and
(III) transfer of antibiotic resistance genes to patients (17).
Tregoning et al. indicate that due to the accumulated
success of multiple phase I clinical studies over the last
decade, the FDA guidelines have become more relaxed over
time (15). Caveats in the FDA guidelines include waivers
of biodistribution studies if the “novel gene is inserted
into a plasmid vector previously documented to have an
acceptable biodistribution/integration profile”, and, that
“integration studies are warranted only when plasmid
persists in any tissue of any animal at levels exceeding
30,000 copies per µg of host DNA by study termination”.
Curiously, the preclinical research studies that established
the precedent for assessing biodistribution/integration
profiles were performed more than a decade ago, prior to
initiation of most human clinical trials (16), and continue
to be referenced as the established precedent for a lack
of detectable biodistribution/integration (18). In looking
toward the future and in light of the numerous DNA
vaccine trials in progress, it might be prudent to re-evaluate
this question using highly sensitive modern molecular 
biology technologies, commonly employed by the gene 
therapy field (19, to profile the human genome for putative 
sites of insertional mutagenesis. 
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